How Gut Bacteria Drive Colorectal Cancer and What Scientists Plan to Do About It

Colorectal cancer is the third most common malignancy worldwide and the second leading cause of cancer-related death, and for decades researchers debated whether the unusual bacterial communities found in tumors were a cause or a consequence. A comprehensive review published in Frontiers in Bioengineering and Biotechnology by Yang Liu and Di Mei of Huludao Central Hospital settles that debate firmly on the causal side, identifying specific pathogens, their molecular signatures, and a roadmap of therapies now moving from bench to bedside.

Fusobacterium nucleatum and pks+ E. coli reshape tumor biology

Three keystone pathogens do most of the documented molecular damage. Fusobacterium nucleatum (Fn) invades colonic epithelial cells using an adhesin called FadA, which disrupts the E-cadherin and beta-catenin complex and effectively hijacks Wnt signaling to accelerate cell proliferation. Research from the National Cancer Institute has zeroed in on a specific subtype, Fna C2, as a likely contributor to tumor growth. Fn also releases lipopolysaccharide that activates tumor-associated macrophages to secrete IL-6, which in turn fires up STAT3 signaling and further suppresses anti-tumor immunity.

pks+ Escherichia coli adds a genotoxic dimension: it manufactures colibactin, a small molecule that induces DNA interstrand crosslinks and drives the kind of genomic instability that can tip a normal cell toward malignancy. Enterotoxigenic Bacteroides fragilis rounds out the trio by secreting B. fragilis toxin (BFT), which degrades E-cadherin through a different route and hyperactivates Wnt/beta-catenin signaling. Studies tracking all three species together confirm that their combined presence correlates with more aggressive disease and poorer outcomes than any single pathogen alone.

Beyond these pathogens, the broader pattern is a loss of microbial diversity. Dysbiotic CRC microbiomes show depleted populations of butyrate-producing bacteria, and the resulting drop in short-chain fatty acids (SCFAs) matters because SCFAs mediate programmed cell death and help maintain epigenetic brakes on oncogenes.

Why colorectal cancer patients face a remodeled immune landscape

The damage these bacteria inflict is not limited to epithelial cells. By chronically activating inflammatory signaling, keystone pathogens reshape the tumor immune microenvironment in ways that blunt the body's surveillance capacity. Macrophages and dendritic cells educated by Fn-derived signals tend to adopt pro-tumor phenotypes, reducing the cytotoxic T-cell activity that would otherwise keep early lesions in check.

This immune remodeling has a direct clinical consequence: patients whose tumors carry high intratumoral bacterial loads show measurably worse prognosis. The bacterial community inside the tumor is not a passive bystander; it appears to be actively negotiating the terms of immune tolerance. That insight opens a therapeutic angle: if bacteria help tumors hide from the immune system, removing or reprogramming those bacteria might restore sensitivity to immunotherapy.

Multi-omics approaches unlock non-invasive screening

Identifying who has a dysbiotic, cancer-associated microbiome before symptoms appear is the next frontier. The review points to multi-omics integration, combining 16S rRNA sequencing with metabolomics and metatranscriptomics, as the method most likely to yield actionable biomarker panels. Advanced sequencing platforms applied to CRC cohorts have already begun characterizing microbial composition and function at a resolution that stool-based DNA tests from a decade ago could not approach.

Bioengineered human organoids and microfluidic Organ-on-a-Chip platforms are solving a longstanding technical headache in this field: the aerobic-anaerobic co-culture paradox that makes it nearly impossible to grow oxygen-sensitive gut anaerobes alongside human cells in standard lab conditions. By recreating the physiological oxygen gradient of the colon, these platforms let researchers study how specific bacterial strains interact with patient-derived epithelial tissue, moving the science from population-level correlations toward patient-specific mechanistic insight.

Open questions about causality and model validation

For all the progress, the review is candid about what remains unresolved. Establishing strict causality is complicated by the fact that nearly all mechanistic data come from cell lines, organoids, or mouse models whose microbiomes and immune systems differ substantially from those of human patients. Translating findings from these systems to clinical predictions requires biomimetic models that have not yet been fully validated against in vivo human responses.

The full delineation of how individual microbes influence tumorigenesis and immune responses also remains incomplete. Fn and pks+ E. coli receive the most attention, but the microbiome contains thousands of species interacting in ways that reductionist studies can miss. Defining which combinations of bacteria drive disease versus merely accompany it is a necessary step before microbiome biomarkers can be trusted in a clinical screening context.

FMT, engineered probiotics, and bacteriophage therapies take aim at CRC

The therapeutic pipeline the review maps is notably diverse. Fecal microbiota transplantation has already demonstrated that it can sensitize patients to anti-PD1 immunotherapy by restoring a favorable bacterial community, and trials are expanding that observation into structured clinical protocols. Narrow-spectrum antimicrobials targeting Fn or B. fragilis without broad collateral damage to commensal species represent a more precise alternative to the blunt instrument of conventional antibiotics; engineered strains of Lactococcus lactis that produce beta-lactamase locally can even buffer commensal populations from antibiotic-induced dysbiosis during treatment.

Bacteriophage-guided drug delivery is a further step: phages can be engineered to seek out specific bacterial strains inside a tumor and deliver payloads, exploiting microbial tropism as a targeting mechanism that chemotherapy does not have. Living engineered probiotics, designed to colonize the tumor microenvironment and secrete immunostimulatory molecules on site, push the concept even further. Each of these microbiota-targeted strategies is still in early-stage development, but the convergence of mechanistic clarity and new engineering tools means the gap between laboratory concept and clinical trial is narrowing faster than it was even five years ago.

The picture that emerges from Liu and Mei's review is of a field that has moved past asking whether the microbiome matters in colorectal cancer and arrived at the harder, more productive question: exactly which bacteria, through which molecular steps, and how do we intervene?